Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin1, Arkadiusz Z Dudek, Theodore F Logan, Raymond S Lance, Jeffrey M Holzbeierlein, Jennifer J Knox, Viraj A Master, Sumanta K Pal, Wilson H Miller, Lawrence I Karsh, Irina Y Tcherepanova, Mark A DeBenedette, W Lee Williams, Douglas C Plessinger, Charles A Nicolette and Robert A Figlin – Journal for Immunotherapy of Cancer 2015, 3:14
Immune Function and Viral Load Post AGS-004 Administration to Chronic HIV Subjects Undergoing STI.
M. DeBenedette, I.Tcherepanova, A., Gamble, J. Horvatinovich, J. Harris, J-P Routy, AGS-004-001 study team, C. Nicolette. Accepted CROI 2014

Multi-Functional Cytotoxic T Cell Expansion Correlates with Overall Survival after Administration of Autologous Dendritic Cell Immunotherapy in Renal Cell Cancer Patients.
M. DeBenedette, I. Jurisica, A. Gamble, W. Lewis, E. Wansley, I. Tcherepanova, C. Nicolette, AGS-003-006 Study Group. Society for Immunotherapy of Cancer. National Harbor MD, November 7-10 2013

Soluble CD83 Ameliorates Experimental Colitis in Mice
J. Eckhardt, S. Kreiser, C. Nicolette, M. A. DeBenedette, I. Y. Tcherepanova, A. Pommer, C. Becker, E. Zinser, A. Steinkasserer and M. Lechmann. Accepted Mucosal Immunology

Patient Identification and Eligibility Challenges in the Synchronous mRCC Population: An Update from the Ongoing ADAPT Phase 3 Study Experience.
B. R. Lane, R. A. Figlin, C. G. Wood, R. G. Uzzo, the SUO-CTC Renal Cancer Committee and the ADAPT Study Group. 14th Annual Meeting of the Society of Urologic Oncology; December 4-6, 2013; Bethesda Maryland. Poster #158

Immunotherapy for HIV: Past, Present and Future.
I. Y. Tcherepanova, C. A. Nicolette HIV Specialist Fall issue 2013 Volume 5 No. 3 p28. Read more

Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B and T cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy
M-A Jenabian , C. A. Nicolette, I. Y. Tcherepanova, M. A. DeBenedette, N. Gilmore, J-P Routy M.D., JAIDS 2013 Volume 64 – Issue 4 – p 345–350 doi: 10.1097/QAI.0b013e3182a4b9ad

Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells and prolongs allogeneic corneal graft survival.
F. Bock, S. Rössner, J. Onderka, M. Lechmann, M. T. Pallotta, F. Fallarino, L. Boon, C. Nicolette, M. A. DeBenedette, I. Y. Tcherepanova, U. Grohmann, A.Steinkasserer, C. Cursiefen, E. Zinser. J Immunol 2013; 191:1965-1975 Read more

Dendritic Cell-Based Immunotherapy in HIV Infection: “A Bridge Over Troubled Water”.
J. Routy, M. Jenabian, C. Nicolette, I. Tcherepanova, R. Sekaly. AIDS Vaccine conference Oct7-Oct10 2013 Barcelona, Spain.

Autologous Dendritic cell based therapy modulates proviral DNA levels in chronically HIV-infected subjects.
I Tcherepanova, J. Harris J. Horvatinovich, M.DeBenedette, Vezina S, Tremblay C, Loutfy M, Gill J, Baril J, Smaill F, J. Angel, J-P Routy, and C. Nicolette. AIDS Vaccine conference Oct7-Oct10 2013 Barcelona, Spain. Poster

Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.
J. G Slagter-Jäger, A. Raney, W. E Lewis, M. A DeBenedette, C. A Nicolette and I. Y Tcherepanova. Molecular Therapy–Nucleic Acids (2013) 2, e91; doi:10.1038/mtna.2013.18 Read more

Prolonged Survival with Personalized Immunotherapy (AGS-003) in Combination with Sunitinib in Unfavorable Risk Metastatic RCC (mRCC)
A. Amin, A.Z. Dudek, T. Logan, R.S. Lance, J.M. Holzbeierlein, V.A. Master, S.K. Pal, J.J.Knox, L.I. Karsh, D. Plessinger, C.A. Nicolette, R.A. Figlin, AGS-003-006 Study Group. ASCO 2013 Genitourinary Cancers Symposium – February 14-16, 2013 – Orlando FL. Abstract # 357.

Considerations for the development of effective cancer immunotherapy Cancer
I. Y. Tcherepanova, M. A. DeBenedette, D. Plessinger, C A. Nicolette. Immunotherapy Clinical Trials: Concepts and Challenges” Workshop (2013) Bethesda MD.

Multi-Functional Cytotoxic T Cell Subsets As Immune Correlates With Clinical Outcomes In A Phase II Study Of AGS-003, An Autologous Dendritic Cell-Based Therapy Administered To Newly Diagnosed, Metastatic RCC Patients.
M. DeBenedette, I. Jurisica, A. Gamble, I.Y. Tcherepanova, W.L. Williams, D. Plessinger, F. Miesowicz, C.A. Nicolette, AGS-003-006 Study Group; Keystone Symposia –Understanding Dendritic Cell Biology to Advance Disease Therapies (C2) March 3-8, 2013 Keystone, Colorado. Poster

Autologous Dendritic Cell Therapy AGS-003, Induces Strong Durable Immune Responses In Patients With Advanced Renal Cell Carcinoma
M. DeBenedette, W. Lewis, E. Wansley, A. Gamble, I.Y. Tcherepanova, C.A. Nicolette. Keystone Symposia –Understanding Dendritic Cell Biology to Advance Disease Therapies (C2) March 3-8, 2013 Keystone, Colorado. Poster

Interferon-alpha Blockade During Acute SIV Infection of Rhesus macaques Reduces T Cell Activation and Restores T Cell Homeostasis
T. Vanderford, C. Steel, J. Zeidan, J. Yu, Y. Zhang, J. Ahlers, C. Nicolette, I. Tcherepanova, M. Cameron, R. Sekaly, G. Silvestri CROI 2013 Atlanta GA. Poster

ADAPT: An Ongoing International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment in Advanced Renal Cell Carcinoma (RCC) 2013 Poster

Identification of multi-functional cytotoxic T cell subsets as immune correlates with clinical outcomes in a phase II study of AGS-003, an autologous dendritic cell-based therapy administered to newly diagnosed, metastatic RCC patients.
M. DeBenedette, I. Jurisica, A Gamble, I.Y. Tcherepanova, W.L. Williams, D. Plessinger, F. Miesowicz, C.A. Nicolette, AGS-003-006 Study Group; Markers in Cancer Oct 11-13, 2012 Hollywood FL

A fully autologous RNA-loaded Dendritic cell-based immunotherapy. Strategies for an HIV cure.
I Tcherepanova. NIH sponsored workshop. November 28-30 (2012) Washington DC.

Autologous dendritic cell-based immunotherapy induces B cells proliferation without impacting regulatory T cells expansion and general immune activation in HIV-infected patients.
M. A. Jenabian, C. A. Nicolette, I.Y. Tcherepanova, M.A. DeBenedette, J. P. Routy. Keystone symposia Immunological Mechanisms of Vaccination, (2012) Ottawa, Canada

Evaluation of a microfluidics-based platform and slab electrophoresis for determination of size, integrity and quantification of in vitro transcribed RNA used as a component in therapeutic drug manufacturing.
J. G. Slagter-Jager, C. A. Nicolette, I Y Tcherepanova. Journal of Pharmaceutical and Biomedical Analysis DOI: 10.1016/j.jpba.2012.04.031

Results of a Randomized Placebo controlled Phase Ia study of AGS-009, a humanized Anti-Interferon-? Monoclonal Antibody in Subjects with Systemic Lupus Erythematosus.
I. Tcherepanova, M. Curtis, M. Sale, F. Miesowicz, and C. Nicolette. Annual European Congress on Rheumatology, EULAR, (2012) Berlin Poster

Improved overall survival (OS) in a phase 2 study combining personalized dendritic cell (DC) based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC)
R. A. Figlin, A. Amin, A. Z. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, V. A. Master, S. K. Pal, A. H. Gamble, M. A. DeBenedette, I. Y. Tcherepanova, W. L. Williams, D. Plessinger, F. Miesowicz, C. A. Nicolette, AGS-003-006 Study Group. ASCO 2012 Genitourinary Cancers Symposium, San Francisco, CA USA (2012). Abstract #348.

Binary tree-structured vector quantization identifies unique clusters of multi-functional T cell responses as immune correlates with subjects´ clinical lab characteristics in a phase II study of AGS-003, an autologous dendritic cell-based therapy.
M. DeBenedette, I Jurisica, A Gamble, R.A. Figlin, A. Amin, A. Dudek, T. Logan, R.S. Lance, J.M. Holzbeierlein, V. A. Master, S.K. Pal, , I.Y. Tcherepanova, W.L. Williams, D. Plessinger, F. Miesowicz, C.A. Nicolette, AGS-003-006 Study Group. Global Technology Community’s (GTC) 4th Immunotherapeutics and Immunomonitoring Conference. (2012) San Diego CA USA. Oral Presentation

Clinical development of a fully autologous RNA-loaded dendritic cell product, AGS-003, for metastatic renal cell carcinoma.
C. Nicolette Phacilitate Cell and Gene Therapy Forum 2012 Washington.

Potency of dendritic cell based immunotherapies is correlated with IL-12 production by tracking the induction of multi-functional CD8+/CD28+ cytotoxic T cell immunity
MA DeBenedette, DM Calderhead, IY Tcherepanova, CA Nicolette, DG Healey. J Immunother. 2011 Jan;34(1):45-57.

Updated immunologic and clinical results from a phase 2 study of AGS-003, an autologous dendritic cell based therapy, in patients with newly diagnosed metastatic renal cell carcinoma in combination with sunitinib.
R. A. Figlin, A. Amin, A. Z. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, S. K. Pal, V. A. Master, M. DeBenedette, I. Y. Tcherepanova, W. L. Williams, T. T. Monesmith, F. Miesowicz, D. Plessinger, C. A. Nicolette, AGS-003-006 Study Group. 10th International Kidney Cancer Symposium (2011) Chicago, IL USA Poster

Monitoring T cell responses in a phase II study of AGS-003, an autologous dendritic cell based therapy in patients with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib
R. A. Figlin, A. Amin, A. Z. Dudek, T. Logan, R. S. Lance, J. M. Holzbeierlein, S. K. Pal, V. A. Master, M. DeBenedette, I. Y. Tcherepanova, R. G. Jain, W. L. Williams, T. T. Monesmith, F. Miesowicz, C. A. Nicolette, AGS-003-006 Study Group. ASCO 2011 Annual Meeting, Chicago, IL USA. (2011). Abstract # 2532.

Final Analysis of a Phase 2 Study of an Autologous Dendritic Cell Immunotherapy (AGS-004) Showed Positive Outcomes in Primary Endpoint of Viral Load Control, and Favorable Safety and Immunogenicity Profile, in Subjects Undergoing Structured Treatment Interruption of ART.
Jean-Pierre Routy, J. Angel , S. Vezina, C. Tremblay, M. Loutfy, J. Gill, J. Baril, F. Smaill, M.-R. Boulassel, I.Y. Tcherepanova, M. DeBenedette, R.G. Jain, C.A. Nicolette and members of the AGS 004-001 study group. 18th Conference on Retroviruses and Opportunistic Infections (2011) Boston MA USA Poster

“Arcelis™ Technology AGS-003: Immunotherapy for mRCC.”
C Nicolette, 2nd World Cancer Vaccines Summit. Boston MA USA.

“Development of AGS-004, a Fully Autologous Therapeutics Vaccine for HIV”
C.Nicolette, Active Immunotherapeutics Forum 2011 Barcelona Spain.

“Arcelis™ Technology AGS-004 Immunotherapy for HIV” on panel discussion titled “Looking to the Future: Innovative Approaches to HIV Vaccine Development and Immunotherapies”
C. Nicolette, (2011) BIO International Convention in Washington D.C. USA

Clinical Development of AGS-004, an Autologous Immunotherapy to Treat HIV infection.
I. Tcherepanova, ImVac The Immunotherapeutics and Vaccine summit. Cambridge Healthtech Institute (2011), Boston MA USA

Prevention of chronic renal allograft rejection by soluble CD83.
Lan Z, Lian D, Liu W, Arp J, Charlton B, Ge W, Brand S, Healey D, DeBenedette M, Nicolette C, Garcia B, Wang H. Transplantation. 2010 Dec 27;90(12):1278-85.

Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2,3-dioxygenase.
Lan Z, Ge W, Arp J, Jiang J, Liu W, Gordon D, Healey D, DeBenedette M, Nicolette C, Garcia B, Wang H Transplantation. 2010 Dec 27;90(12):1286-93.

Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection.
Ge W, Arp J, Lian D, Liu W, Baroja ML, Jiang J, Ramcharran S, Eldeen FZ, Zinser E, Steinkasserer A, Chou P, Brand S, Nicolette C, Garcia B, Wang H. Transplantation. 2010 Dec 15;90 (11):1145-56.

Structural identification of recombinant human CD83 mutant variant as a potent therapeutic protein.
Zhang L, Narayanan N, Brand SR, Nicolette CA, Baroja M, Arp J, Wang H, Moo-Young M, Chou CP. Protein Expr Purif. 2010 Oct;73(2):140-6. Epub 2010 Jun 8.

Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection
Routy JP, Nicolette C. Immunotherapy. 2010 Jul; 2(4):467-76.

A Short Pulse of IL-4 Delivered by DCs Electroporated With Modified mRNA Can Both Prevent and Treat Autoimmune Diabetes in NOD Mice.
RJ Creusot, P Chang, DG Healey, IY Tcherepanova, CA Nicolette and CG Fathman. Molecular Therapy (2010); 18 12, 2112–2120 Read more

Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
Routy J, Boulassel M, Yassine-Diab Y, Nicolette C, Healey D, Jain R, Landry C, Yegorov O, Tcherepanova I, Monesmith T, Finke L and Sekaly R. Clin. Immunol., 134, 140-147 (2010).
Read more

Development of a cellular immunotherapy for ART naïve patients for the purpose of delaying or preventing initiation of ART therapy.
I.Y. Tcherepanova, D.M. Calderhead, M.A. DeBenedette, R.Jain, J.P. Routy, C.A. Nicolette HIV DART (2010), Los Cabos, Mexico. Poster

A Phase 1/2 Study of AGS-003, a personalized immunotherapeutic evaluated in newly diagnosed metastatic renal cell carcinoma subjects
T. Logan, A. Amin, V. Cohen, M. K. K. Wong, V. A. Master, T. Monesmith, D. Healey, R. Jain, D. Plessinger, C. A. Nicolette. ASCO 2010 Genitourinary Cancers Symposium, San Francisco, CA (2010). Abstract # 379.

Mature Dendritic Cells Electroporated with CD40L RNA Produce IL-12 a Critical Component of Dendritic Cell Based Immune-Therapy Necessary for the Induction of Multi-Functional Effector/Memory CD8+/CD28+ CTL.
M. DeBenedette, D. Calderhead, I. Tcherepanova, C. Nicolette and D. Healey. Keystone Symposia – Immunological Mechanisms of Vaccination (S1) (2010) Seattle, WA USA

Cancer Immunotherapy: A long awaited reality.
October 21, 2010 New York Academy of Medicine New York City. AN EXCLUSIVE CONFERENCE EVENT & TELEVISED SERIES. Fred Miesowicz and Charles Nicolette presentation.

Webinar with leading researchers in renal cell carcinoma (RCC) to discuss novel therapies, recently approved or in development, as well as the promise of personalized immunotherapy in the treatment of RCC.
November 1, 2010 (Webinar link)

The Argos Approach to Personalized Dendritic Cell Immunotherapies.
F. Miesowicz. ISPE Fall Annual Gala for the local CASA chapter in Cary, NC USA (2010)

Assessing & Implementing Automation session/panel discussion.
F. Miesowicz. Cell Therapy Industry Summit hosted by Invitrogen Carlsbad, CA Nov 2010

Process Development and Clinical Manufacturing for Autologous Dendritic Cell Immunotherapies
T. Monesmith. BioProcess International Conference and Convention Providence RI USA (Sep 2010)

Encouraging progression free survival results in subjects with newly diagnosed advanced stage renal cell carcinoma (RCC) participating in a phase II study testing the safety and activity of a dendritic cell-based immunotherapeutic (AGS-003) in combination with sunitinib
RA Figlin, A Amin, AZ Dudek, T Logan, RS Lance, JM Holzbeierlein, WL Williams, RG Jain, T. Monesmith, I. Tcherepanova, F Miesowicz, CA Nicolette, AGS-003-006 Study Group. Ninth International Kidney Cancer Symposium Chicago, IL USA (2010) Poster

An autologous AI approach to treating HIV infection.
CA Nicolette, IY Tcherepanova, D Healey, D Calderhead, M DeBenedette, R Jain, WL Williams, T Monesmith, F Miesowicz, JP Routy, J Jacobson, AGS-004-001 Study Group. Active Immunotherapeutics forum, Barcelona, Spain (2010)

A phase II study testing the safety and activity of AGS-003 as an immunotherapeutic in subjects with newly diagnosed advanced stage renal cell carcinoma in combination with sunitinib
A Amin, AZ Dudek, T Logan, RS Lance, JM Holzbeierlein, WL Williams, RG Jain, IY Tcherepanova, CA Nicolette, TT Monesmith, RA Figlin, AGS-003-006 Study Group. ASCO 2010 Annual Meeting (2010) Chicago, IL USA, Abstract # 4588

A novel method to improve antigen presentation and immunopotency of RNA-loaded monocyte-derived dendritic cells.
I. Tcherepanova, A. Raney, B. Martin, M. Norris, T. Monesmith, M. DeBenedette, F. Miesowicz, and C.A. Nicolette. 22 nd EORTC-NCI-AACR (2010) Berlin.
Poster

Evaluation of the Agilent Bioanalyzer 2100 for quality determination of IVT RNA.
JG Slagter-Jäger, C Nicolette and I Tcherepanova. 15th Annual Meeting of RNA society, Seattle WA, USA (2010).

Immunologic activity of a fully autologous dendritic cell immunotherapy for the treatment of HIV-1 infected subjects.
D Healey, B Yassine-Diab, Z Coutsinos, C Landry, D Gagnon, C Hebert-Benoit, R Boulassel, JP Routy, S Vezina, C Tremblay, M Loutfy, F Smaill, J Gill, JG Baril, R Jain, I Tcherepanova, and RP Sekaly, CA Nicolette. XVIII International AIDS Conference, Vienna, Austria (2010).

HIV-1 infected subjects treated with an autologous dendritic cell therapy (AGS-004), exhibited a significant reduction in viral load (when compared to pre-ART viral load) and delay in the time to viral rebound during a 12 week structured treatment interruption (STI).
J.P. Routy, J. Angel, S. Vezina, C. Tremblay, M. Loutfy, J. Gill, J.G. Baril, F. Smaill, R. Jain, I. Y. Tcherepanova, R. Boulassel, T. Monesmith, R. P. Sekaly, C. A. Nicolette, AGS 004-001 Study Group. XVIII International AIDS Conference, Vienna, Austria (2010). Poster # MOPDB101.

AGS-004, an autologous dendritic cell therapy impacts on the evolution of residual HIV virus along with a substantial increase in time to viral rebound, during an STI in the CTN 239 clinical study
Tcherepanova I, Boulassel MR, Carreno A, Carpenter H, Loutfy MR, Vezina S, Tremblay C, Angel, J, Gill J, Baril, J, Smaill F, Jain R, Healey D, Chew T , Nicolette C. and Routy JP. 19th Annual Canadian Conference on HIV/AIDS Research, Saskatoon, Canada (2010).

Study of rebound virus genetic diversity in subjects treated with autologous DC based (AGS-004) immunotherapy after ART interruption.
I.Y. Tcherepanova, A.D. Carreño, J.H. Carpenter, J. Harris, J.P. Routy, R. Jain, D. Healey, T. Chew and C.A. Nicolette. Keystone Symposium: HIV Vaccines. Banff, Canada (2010)

Challenges of Manufacturing Autologous Cell Therapies.
T. Monesmith NC State ISPE student chapter Raleigh NC, USA (2010)

Safety and Viral load changes in HIV-1 infected subjects treated with autologous dendritic immune therapy following ART discontinuation.
Routy J, Boulassel M, Loutfy M, Vezina S, Tremblay C, Angel J, Gill J, Baril J, Smaill F, Jain R, Healey D, Tcherepanova I, Nicolette C and Sekaly R. Oral Presentation

Bioprocess development for production, purification, and structural characterization of recombinant hCD83ext as a potential therapeutic protein.
Xu Y, Zhang L, Yao W, Yedahalli SS, Brand S, Moo-Young M, Perry Chou C. Protein Expr Purif. 2009 May;65(1):92-9.

Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals.
AIDS Vaccine Conference, October 19-22 2009. Paris, France Yassine DB, Coustinos Z, Landry C, Gagnon D, Sauve D, Herbert-Benoit C, Hebert V, Levesque G, Kay P, Bounif N, Boulassel M, Routy J, Jain R, Tcherepanova I, Healey D, Nicolette C and Sekaly R. Poster presentation

Assessing risk of a 12- week antiretroviral therapy discontinuation as a read out of viral control in immune-based therapy (AGS-004-001).
5th International IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 19-22 2009 Cape Town, South Africa Routy J, Jain R, Boulassel M, Nicolette C, Finke L and Jacobson J. Poster No MOPEB092.

Safety and feasibility of a multicentre phase 2 trial using autologous dendritic cell (DC) therapy to control viral replication following ART discontinuation (CTN#239).
Canadian Association of HIV Researchers, Vancouver, April 23-25th 2009 Routy J, Vezina S, Tremblay C, Baril J, Loutfy M, Gill J, Jain R, Nicolette C, Sekaly R and Boulassel MR for the CTN 239 investigators

A Nursing Perspective of Apheresis Procedures Performed in HIV-Infected Subjects Receiving a Monocytes-Derived Dendritic Cell-Based Immunotherapy.
D Feng , C Goupil , J Mathieu , M. Delisle, S Girard , C Landry , C Gagné , M Swidzinski, MR Boulassel , JP Routy for the CTN-239 Study Investigators

The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.
Keystone HIV Immunobiology 2009 — Irina Tcherepanova, Aijing Starr, Melissa Adams. Brad Lackford, David Calderhead, Don Healey, Mohamed-Rachid Boulassel, Jean-Pierre Routy and Charles Nicolette
Read more

Soluble CD83 promotes tolerance induction to minor mismatched skin transplants and allogeneic heart transplants in the mouse.
10th International Symposium on Dendritic Cells, 2009 Elisabeth Zinser, Hao Wang, Stephen Brand, Charles Nicolette, Robert Zhong, William J. Wall and Alexander Steinkasserer

Soluble CD83 Mediated Suppression of B-cell Activation and Differentiation Prolongs Murine Cardiac Allograft Survival.
American Society of Transplantation Congress 2009 Wei Ge, Siobhan I. Ramcharran, Jacqueline Arp, Miren L. Baroja, Zhu Lan, Jifu Jiang, Weihua Liu, Anthony Jevnikar, Stephen Brand, Charles Nicolette, Bertha Garcia, and Hao Wang

Modulation of Dendritic Cells by Soluble CD83 Induces Kidney Allograft Tolerance.
Zhu Lan, Wei Ge, Miren L. Baroja, Jacqueline Arp, Jifu Jiang, Weihua Liu, Stephen Brand, Charles Nicolette, Bertha Garcia, and Hao Wang

Soluble CD83: Its Safety and Efficacy in a Non-Human Primate Kidney Allotransplantation Model.
M L Baroja, Z Lan, J Arp, Weihua LiuG,Strejan, S Brand, C Nicolette, W Wall, B Garcia, D M Rothstein, A M Jevnikar, and H Wang

The Soluble Extracellular Domain of CD83 is Capable of Generating Regulatory T Cells in Non-Human Primates.
American Society of Transplantation Congress 2008 Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, William Wall, and Hao Wang

Multiplex RT-PCR amplification of HIV genes to create a completely autologous DC-based immunotherapy for the treatment of HIV infection.
Tcherepanova I, Harris J, Starr A, Cleveland J, Ketteringham H, David Calderhead, Joe Horvatinovich, Don Healey, Charles A Nicolette. PLoS ONE 3(1): e1489. doi:10.1371/journal.pone.0001489 2008
Read more

Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion.
Irina Y Tcherepanova, Melissa D Adams, Xiaorong Feng, Atsushi Hinohara, Joe Horvatinovich, David Calderhead, Don Healey and Charles A Nicolette. BMC Molecular Biology 2008, 9:90 doi:10.1186/1471-2199-9-90
Read more

Priming of a novel subset of CD28: rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells Is IL-12 dependent.
Mark A. DeBenedette, David M. Calderhead, Helen Ketteringham, Alicia H. Gamble, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, and Don G. Healey. The Journal of Immunology, 2008, 181: 5296–5305.
Read more

Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.
David M. Calderhead, Mark A. DeBenedette, Helen Ketteringham, Alicia H. Gamble, Joe M. Horvatinovich, Irina Y. Tcherepanova, Charles A. Nicolette, and Don G. Healey. J Immunother 2008; 31:731–741

An automated approach for manufacturing personalized dendritic cell immunotherapies.
ISCT 14th Annual Meeting 2008 Monesmith T., Williams L., Martin B., Peel T., Kneen D., Spence S., Grant R., Miesowicz F.

Autologous dendritic cell immunotherapeurtic (Arcelis™ for HIV): tolerability and immunogenicity in HIV-1 infected subjects treated with ART.
XVII International AIDS Conference 2008 Routy, JP, Yassine-Diab, B, Laundry, C, Yegorov, O, Boulassel MR, Benoit-Hebert, C. Antar, R., Tcherepanova, I., Healey, D., Jain R., Finke L, Nicolette, C., Sekaly RP.

A Phase I safety and feasibility study of autologous dendritic cell therapy in ART treated HIV infected subjects (CAN-HIV-001)
Keystone HIV Vaccine 2008 JP Routy, NR Boulassel, C Laundry, B Yassine-Diab, R Antar, I Tcherepanova, D Healey, F Miesowicz, C Nicolette, LH Finke, RP Sekaly.

Post transcriptionally capped HIV RNAs confer higher antigen expression level in DCs.
Keystone HIV vaccine meeting – I Tcherepanova, A Starr, A Raney, D Calderhead, J Horvatinovich, D Healey, C Nicolette

IL-12 as an immunopotency marker for fully autologous dendritic cell immunotherapeutics.
23rd Annual Meeting of ISBTC 2008 – D Healey, D Calderhead, A Gamble, J Horvatinovich, Helen Ketterningham, I Tcherepanova, C Nicolette and M DeBenedette

The Soluble Extracellular Domain of CD83 is Capable of Generating Regulatory T Cells in Non-Human Primates.
American Society of Transplantation Congress 2008 Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, William Wall, and Hao Wang

Soluble CD83 mediated B cell suppression prolongs murine allograft survival
American Society of Transplantation Congress 2007 Siobhan Ramcharan, Jacqueline Arp, Miren Baroja Stephen Brand, Gill Strejan, Hao Wang, Anthony M. Jevnikar, and Robert Zhong

Immunosuppressive properties of soluble extracellular domain of CD83 on antigen-presenting cells of cynomologous monkey
Miren Baroja, Jacqueline Arp, Siobhan Ramcharan, Stephen Brand, Anthony M. Jevnikar, Gill Strejan, Hao Wang, William Wall, and Robert Zhong

Targeting a novel immunomodulatory protein by soluble CD83 promote tolerance induction in a mouse cardiac transplantation model
Hao Wang, Wei Ge, Weihua Liu, Dameng Lian, Miren Baroja, Siobhan Ramcharan, Bertha Garcia, Robert Zhong, William Wall

Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
Nicolette C, Healey D., Tcherepanova I., Whelton P., Monesmith T., Coombs L., Finke L., Whiteside T., and Miesowicz F. Vaccine V 25, 2007 pp B48-B60

PME CD40L DC prime the expansion of CD28+/CD45RA long lived effector memory CTL having clinical relevance for dendritic cell based immunotherapies
22nd Annual Meeting of ISBTC 2007 Don Healey, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Irina Tcherepanova, Charles Nicolette, Mark DeBenedette

Sorafenib but not Sunitinib inhibits human T-cell function in vitro: Implications for combined TKI and Immunotherapy strategies for the treatment of cancer.
Don Healey, David Calderhead, Alicia Gamble, Helen Ketteringham, Robert Figlin, Harry Drabkin, Lothar Finke, Charles Nicolette, Mark DeBenedette

PME-CD40L DC Prime the Expansion of CD28+/CD45RA- Long Lived Effector Memory CTL Having Clinical Relevance for Dendritic Cell Based Immunotherapies
Mark DeBenedette, David Calderhead, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and Don Healey
Keystine Sympoisa-Immunolgical Intervention in Human Disease Big Sky Montana January 6-11 2007

Development of CD4 independent primary CD8 CTL activity in vitro by co-transfection of RNAs encoding antigen and CD40L into prematured DC
Keystone Symposium 2007: “Immunological Intervention in Human Disease” David Calderhead, Mark DeBenedette, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and Don Healey

Large-Scale Production of Autologous CD14+-Monocyte Derived Dendritic Cells Co-Electroporated with Amplified Total Tumour mRNA and Human CD40L mRNA in Patients with B-Cell Chronic Lymphocytic Leukemia.
G. Fraser, D. Healey, J. C. Rodriguez-Lecompte, K.Suresh, P. O’Hoski, I. Tcherepanova, M. DeBenedette, C. Nicolette, J. Gauldie, R. Foley. American Society of Hematology meeting abstract special issue Blood, 108, 11, (2006)

Novel method of DC maturation: intracellular ligation of CD40 by a truncated CD154 encoded by RNA
I.Y. Tcherepanova, M. Adams, A. Hinohara, J. Horvatinovich, D. Healey, and C.A. Nicolette.. J. Immunotherapy, Abstracts of 21st Annual Meeting of ISBT, 29, 670 (2006).

Novel customized DC based immunotherapy tailored to the infecting patient’s HIV: from conception to clinic.
9th International Conference Drug and Gene Based Therapeutics Crete Greece 2006 I. Tcherepanova

Autologous Nef RNA HIV-1 Electroporated DC enhances the detection of CD8-specific proliferative responses.
13th Annual Meeting CROI 2006 (Denver) Oleg Yegorov, Bader Yassine-Diab,Tom Baumgartner, Rachid Boulassel , Jean-Pierre Routy, Don Healey, Irina Tcherepanova, Charles Nicolette and Rafick-Pierre Sekaly

Optimization of autologous RNA transfected DC therapy product
Keystone HIV Vaccine 2006 Irina Tcherepanova, Brad Lackford, Jason Harris, Don Healey, Joe Horvatinovich, Charles Nicolette

Development of CD4 independent primary CD8 CTL activity in vitro by co-transfection of RNAs encoding antigen and CD40L into pre-matured DC
9th International Conference on Dendritic Cells 2006 Don Healey, Mark DeBenedette, Alicia Gamble, Joe Horvatinovich, Helen Ketteringham, Melissa Adams, Brad Lackford, Irina Tcherepanova, Charles Nicolette and David Calderhead

Novel Method of DC Maturation: Intracellular Ligation of CD40 by a truncated CD154 encoded by RNA.
21st Annual Meeting of ISBT 2006 I Tcherepanova., Adams M., Hinohara A., Horvatinovich., J., Healey D., Nicolette C., J. Immunotherapy, Abstracts of 21st annual meeting of ISBT V 29 n6 2006 p670.

An improved RNA amplification procedure results in increased yield of autologous RNA transfected dendritic cell-based vaccine.
Jason Harris, Tamara Monesmith, Alicia Ubben, Marcus Norris, Jonathan H Freedman, Irina Tcherepanova. Biochim Biophys Acta. 2005 Jun 20;1724 (1-2):127-36

Autologous RNA transfected dendritic cell based anti HIV vaccine.
Keystone HIV Vaccine 2005, I. Tcherepanova., Harris J., Lackford B., Calderhead D.

Autologous HIV electroporated DC enhances the detection of CD8 specific proliferative responses.
AIDS Vaccine 2005 (Montreal) O. Yegorov, Yassine Diab B., Chambenoit O., Gangon B., Boulassel R., Routy JP., Healey D., Harris J., Tcherepanova I., Nicolette C., Sekaly RP.

A novel strain-independent anti HIV vaccine targets autologous virus and its quasispecies.
AIDS Vaccine 2005 (Montreal) Tcherepanova I., Harris J., Lackford B., Yassine Diab., B., Yegorov O., Sekaly RP., Nicolette C.

Development of CD4+ independent CD8+ CTL activity in vitro by transfection of CD154 (CD40 ligand) mRNA into dendritic cells
Keystone Symposium 2005: “Dendritic Cells at the Center of Innate and Adaptive Immunity: Eradication of Pathogens and Cancer and Control of Immunopathology” David Calderhead, Alicia Hedgepeth, Helen Ketteringham, Joe Horvatinovich, Charles Nicolette and Don Healey

Dendritic cell subsets generated from CD34(+) hematopoietic progenitors can be transfected with mRNA and induce antigen-specific cytotoxic T cell responses.
Hideki Ueno, Irina Tcherepanova, Olivier Reygrobellet, Erik Laughner, Claire Ventura, A Karolina Palucka, Jacques Banchereau. J Immunol Methods. 2004 Feb 15;285 (2):171-80

Flu-MP RNA-transfected subsets of CD34-HPCs derived DCs induce potent recall immune responses.
Keystone 2004 Hideki Ueno, Irina Tcherepanova, Olivier Reygrobellet, Claire Ventura, A. Karolina Palucka and Jacques Banchereau. Baylor Institute for Immunology Research Dallas, TX and Merix Bioscience, Inc